The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site.
Details
Serval ID
serval:BIB_AECE4D25C507
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site.
Journal
The American journal of medicine
Working group(s)
RIETE investigators
Contributor(s)
Aibar M.A., Arcelus J.I., Ballaz A., Barba R., Barrón M., Barrón-Andrés B., Bascuñana J., Blanco-Molina A., Bueso T., Casado I., Culla A., de Miguel J., Del Toro J., Díaz-Peromingo J.A., Falgá C., Fernández-Capitán C., Font C., Font L., Gallego P., García-Bragado F., García-Brotons P., Gómez V., González J., Grau E., Grimón A., Guirado L., Gutiérrez J., Hernández G., Hernández-Blasco L., Isern V., Jara-Palomares L., Jaras M.J., Jiménez D., Lacruz B., Lecumberri R., Lobo J.L., López-Jiménez L., López-Reyes R., López-Sáez J.B., Lorente M.A., Lorenzo A., Madridano O., Marchena P.J., Martín-Antorán J.M., Martín-Martos F., Monreal M., Morales M.V., Nauffal D., Nieto J.A., Nieto S., Núñez M.J., Otalora S., Otero R., Pagán B., Pedrajas J.M., Pérez C., Pérez G., Peris M.L., Porras J.A., Ramírez L., Reig O., Riera A., Rivas A., Rodríguez-Dávila M.A., Rosa V., Ruiz-Artacho P., Ruiz-Giménez N., Ruiz-Martínez C., Sampériz A., Sala C., Sanz O., Soler S., Sopeña B., Suarez I., Suriñach J.M., Tiberio G., Tolosa C., Trujillo-Santos J., Uresandi F., Valle R., Vela J., Villalta J., Malfante P.C., Verhamme P., Wells P., Hirmerova J., Malý R., Tomko T., Salgado E., Bertoletti L., Bura-Riviere A., Farge-Bancel D., Hij A., Mahé I., Merah A., Papadakis M., Braester A., Brenner B., Tzoran I., Apollonio A., Barillari G., Candeloro G., Ciammaichella M., Di Micco P., Ferrazzi P., Grandone E., Lessiani G., Lodigiani C., Mastroiacovo D., Pace F., Pinelli M., Prandoni P., Rota L., Tiraferri E., Tufano A., Visonà A., Belovs A., Skride A., Moreira M., Ribeiro J.L., Sousa M.S., Bosevski M., Zdraveska M., Alatri A., Bounameaux H., Calanca L., Mazzolai L., Serrano J.C., Decousus H., Reis A.
ISSN
1555-7162 (Electronic)
ISSN-L
0002-9343
Publication state
Published
Issued date
03/2017
Peer-reviewed
Oui
Volume
130
Number
3
Pages
337-347
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
We hypothesized that the clinical course of venous thromboembolism in patients with active cancer may differ according to the specificities of primary tumor site.
We used data from RIETE (international registry of patients with venous thromboembolism) to compare the clinical venous thromboembolism-related outcomes during the course of anticoagulation in patients with one of the 4 more frequent cancers (breast, prostate, colorectal, or lung cancer).
As of September 2014, 3947 cancer patients were recruited, of whom 938 had breast, 629 prostate, 1189 colorectal, and 1191 lung cancer. Overall, 55% had metastatic disease (42%, 36%, 53%, and 72%, respectively). During the course of anticoagulant therapy (mean duration, 139 days), the rate of thromboembolic recurrences was similar to the rate of major bleeding in patients with breast (5.6 [95% confidence interval (CI), 3.8-8.1] vs 4.1 [95% CI, 2.7-5.9] events per 100 patient-years) or colorectal cancer (10 [95% CI, 7.6-13] vs 12 [95% CI, 9.4-15] per 100 patient-years). In contrast, in patients with prostate cancer, the rate of venous thromboembolic recurrences was half the rate of major bleeding (6.9 [95% CI, 4.4-10] vs 13 [95% CI, 9.2-17] events per 100 patient-years), whereas in those with lung cancer, the rate of thromboembolic recurrences was twofold higher than the rate of major bleeding (27 [95% CI, 22-23] vs 11 [95% CI, 8.6-15] per 100 patient-years).
Significant differences in the clinical profile of venous thromboembolic-related outcomes were observed according to the site of cancer. These findings suggest the development of cancer-specific anticoagulant strategies as an area for further research.
We used data from RIETE (international registry of patients with venous thromboembolism) to compare the clinical venous thromboembolism-related outcomes during the course of anticoagulation in patients with one of the 4 more frequent cancers (breast, prostate, colorectal, or lung cancer).
As of September 2014, 3947 cancer patients were recruited, of whom 938 had breast, 629 prostate, 1189 colorectal, and 1191 lung cancer. Overall, 55% had metastatic disease (42%, 36%, 53%, and 72%, respectively). During the course of anticoagulant therapy (mean duration, 139 days), the rate of thromboembolic recurrences was similar to the rate of major bleeding in patients with breast (5.6 [95% confidence interval (CI), 3.8-8.1] vs 4.1 [95% CI, 2.7-5.9] events per 100 patient-years) or colorectal cancer (10 [95% CI, 7.6-13] vs 12 [95% CI, 9.4-15] per 100 patient-years). In contrast, in patients with prostate cancer, the rate of venous thromboembolic recurrences was half the rate of major bleeding (6.9 [95% CI, 4.4-10] vs 13 [95% CI, 9.2-17] events per 100 patient-years), whereas in those with lung cancer, the rate of thromboembolic recurrences was twofold higher than the rate of major bleeding (27 [95% CI, 22-23] vs 11 [95% CI, 8.6-15] per 100 patient-years).
Significant differences in the clinical profile of venous thromboembolic-related outcomes were observed according to the site of cancer. These findings suggest the development of cancer-specific anticoagulant strategies as an area for further research.
Pubmed
Create date
14/02/2017 12:47
Last modification date
20/08/2019 16:18
Usage data
